Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P50549
UPID:
ETV1_HUMAN
Alternative names:
Ets-related protein 81
Alternative UPACC:
P50549; A4D118; B2R768; B7Z2I4; B7Z618; B7Z9P2; C9JT37; E9PHB1; F5GXR2; O75849; Q4KMQ6; Q59GA7; Q6AI30; Q9UQ71; Q9Y636
Background:
ETS translocation variant 1, also known as Ets-related protein 81, is a transcriptional activator that binds to DNA sequences featuring the consensus pentanucleotide 5'-CGGA[AT]-3'. It plays a crucial role in olfactory dopaminergic neuron differentiation, potentially activating the expression of tyrosine hydroxylase, a key enzyme in dopamine synthesis.
Therapeutic significance:
ETS translocation variant 1 is implicated in the pathogenesis of Ewing sarcoma, a highly malignant tumor affecting children and adolescents. The protein's involvement is marked by a chromosomal aberration, specifically translocation t(7;22)(p22;q12) with EWSR1. Understanding the role of ETS translocation variant 1 could open doors to potential therapeutic strategies for this aggressive cancer.